Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

48.20
+1.322.82%
Post-market: 47.49-0.7100-1.47%17:21 EDT
Volume:1.22M
Turnover:58.72M
Market Cap:2.96B
PE:11.39
High:48.93
Open:46.68
Low:46.39
Close:46.88
Loading ...

Protagonist Therapeutics price target raised to $67 from $51 at BTIG

TIPRANKS
·
22 Nov 2024

Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Nov 2024

U.S. RESEARCH ROUNDUP- CPI Card Group, First Solar, Viking Therapeutics

Reuters
·
22 Nov 2024

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

ACCESSWIRE
·
22 Nov 2024

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

ACCESSWIRE
·
19 Nov 2024

TD Cowen Remains a Buy on Protagonist Therapeutics (PTGX)

TIPRANKS
·
19 Nov 2024

Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Nov 2024

Protagonist Therapeutics Inc Shares Down 5.9% at $38 in Relatively Light Trading Volume After the Bell Following Update From Phase 3 Study of Plague Psoriasis Treatment

THOMSON REUTERS
·
19 Nov 2024

Protagonist and JNJ say icotrokinra study for PsO meets endpoint

TIPRANKS
·
19 Nov 2024

Protagonist Therapeutics-Iconic-Lead Achieved Its Co-Primary Endpoints of Pasi-90 and Iga of 0 or 1 at Week 16

THOMSON REUTERS
·
19 Nov 2024

Protagonist Therapeutics Inc -Positive Topline Results From Phase 3 Iconic Studies of Icotrokinra (Jnj-2113) in Plaque Psoriasis

THOMSON REUTERS
·
19 Nov 2024

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor

ACCESSWIRE
·
19 Nov 2024

Truist Financial Issues a Buy Rating on Protagonist Therapeutics (PTGX)

TIPRANKS
·
18 Nov 2024

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know

Zacks
·
14 Nov 2024

Protagonist Therapeutics (PTGX) Receives a Buy from Truist Financial

TIPRANKS
·
13 Nov 2024

Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Nov 2024

Bullish Outlook on Protagonist Therapeutics Amid Promising JNJ-2113 Phase 3 Trial Potential

TIPRANKS
·
11 Nov 2024

Protagonist Therapeutics (PTGX) Gets a Buy from J.P. Morgan

TIPRANKS
·
09 Nov 2024

Protagonist Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
08 Nov 2024

Positive Outlook and Buy Rating for Protagonist Therapeutics Based on Promising Phase III Results and Strategic Positioning

TIPRANKS
·
08 Nov 2024